Previous 10 | Next 10 |
home / stock / sva:cc / sva:cc news
(TheNewswire) LONDON, Ontario; BOSTON, Massachusetts – TheNewswire – May 1, 2024, Sernova Corp. (“Sernova” or the “Corporation”) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH) a clinical-stage biotechnology company focused on the de...
(TheNewswire) Dr. Philip Toleikis to retire as of April 30, 2024 Cost savings from restructuring and strategic transformation anticipated to extend runway Board rebuild underway LONDON, Ontario; BOSTON, Massachusetts – TheNewswire - April 25, 2024 ...
(TheNewswire) Dr. Daniel Mahony to step down to pursue new commitment LONDON, Ontario; BOSTON, Massachusetts – April 22, 2024 – TheNewswire – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on t...
A look at the top 10 most actives in Canada Bank of Nova Scotia (The) (BNS) fell 1.3% to $67.64 on volume of 2,485,966 shares Toronto-Dominion Bank (The) (TD) fell 1.2% to $79.21 on volume of 2,433,359 shares Power Corporation of Canada Subordinate Voting Shares (POW) fell 1.5% to $37.25 ...
(TheNewswire) Type 1 diabetes (T1D) Cohort 2 patient data demonstrates favorable islet engraftment and long-term survival of human donor islets in the Cell Pouch First treated Cohort 1 patient in the T1D clinical trial to celebrate four years of insulin independence and ...
2024-03-27 17:08:02 ET © 2020 www.B-TV.com . All Rights Reserved. Regenerative medicine solution that could be used for diabetes and other chronic diseases Sernova is a regenerative medicine therapeutics company. They are developing therapeutics platform technologies ...
2024-03-27 17:08:02 ET A new approach to treating chronic diseases Sernova is a regenerative medicine therapeutics company. They're developing therapeutics platform technologies to treat chronic diseases through a regenerative medicine approach. The company's primary focus is the ...
2024-03-27 17:08:02 ET A new approach to treating chronic diseases including Type 1 Diabetes Sernova is developing therapeutics platform technologies to treat chronic diseases through a regenerative medicine approach. Further, the company's primary focus is the development of ...
(TheNewswire) LONDON, Ontario; BOSTON, Massachusetts – TheNewswire - March 11, 2024 – Sernova Corp. (TSX:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage company focused on providing regenerative medicine therapeutics to patients with chronic conditions, today announ...
(TheNewswire) Recently completed recruitment of all 7 patients in Cohort 2 Anticipates additional data from Cohort 2 of Phase 1/2 clinical trial evaluating its enhanced 10-channel Cell Pouch in patients with type 1 diabetes (T1D) in Q1/24 Expects to report precli...
News, Short Squeeze, Breakout and More Instantly...
(TheNewswire) LONDON, Ontario; BOSTON, Massachusetts – TheNewswire - July 15, 2024 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment o...
(TheNewswire) To date Sernova reports 7 patients in its Phase I/II type 1 diabetes clinical trial achieved freedom from insulin injections and demonstrate blood sugar control in the non- diabetic range (HbA1c 6.5%); 6 patients have reached between 5.5 and 50 months o...
(TheNewswire) LONDON, Ontario; BOSTON, Massachusetts – June 12, 2024 – TheNewswire – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatmen...